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Abstract
Background: Following an epidemiological study carried out in 2006 showing a high prevalence of blinding trachoma in the
Far North Region of Cameroon, a trachoma elimination programme using the SAFE strategy was initiated: three yearly
trachoma mass treatments were to be performed.
Methodology/Principal Findings: The entire district population (120,000 persons) was treated with azithromycin 1.5% eye
drops in February 2008 and January 2009. To assess the effect of treatment on the prevalence of active trachoma, three
epidemiological studies were conducted on a representative sample of children aged between 1 and 10 years. The first
study was performed just prior to the first treatment, the second just prior to the 2nd treatment and the third one, one year
later. The prevalence of active forms of trachoma (TF + TI) dropped from 31.5% (95%CI 26.4–37.5) before treatment to 6.3%
(95%CI 4.1–9.6) one year after first treatment; a reduction of nearly 80%. One year after the second treatment, the
prevalence decreased to 3.1% (95%CI 2.0–4.9), a total reduction of 90%. Furthermore, there were no more TI cases (only TF).
There was no report of serious or systemic side effects. Tolerance was excellent.
Conclusions/Significance: Active trachoma mass treatment with azithromycin 1.5% eye drops is feasible, well tolerated, and
effective.
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Introduction
Trachoma is caused by Chlamydia trachomatis and it is spread by
direct contact with eye, nose, and throat secretions from affected
individuals or by contact with objects, such as towels and/or
washcloths, which have had similar contact with these secretions
[1,2]. Flies can also be a route of mechanical transmission [1].
Children are the most susceptible to infection but the blinding
effects or more severe symptoms are often not felt until adulthood.
Infection is frequently passed from child to child but also from
child to mother. Indeed, women are nearly two times [3] more
affected than men by trachoma and trichiasis, probably because
one of the primary activities of girls is taking care of their younger
family members. This activity continues into adulthood, with
women carrying the main responsibility of caring for children.
Trachoma remains the leading infectious cause of blindness in
the world [4]. Mass oral azithromycin distribution has been used
in several programs. At present, azithromycin is available in a
1.5% eye drop formulation in Europe, Maghreb and French
speaking African countries. The National Blindness Prevention
Programme and a Vision 2020 plan were established as a result of
the prevention policy of the Republic of Cameroon., In December
2006, in the Kolofata Health District (Far North Cameroon), a
study assessing the prevalence of active and scarring trachoma,
signalled the presence of endemic trachoma with significant
blinding potential [5]. The National Blindness Prevention
Programme decided to plan an elimination program by imple-
menting the SAFE (Surgery, Antibiotics, Facial cleanliness, and
Environmental change) strategy [6], addressing the ‘‘A’’ (antibi-
otic) component by conducting mass treatment targeting the entire
district population and using azithromycin 1.5% eye drops. The
objective of this study was to assess the feasibility, tolerance and
effectiveness of repeated topical mass treatment with azithtromy-
cin 1.5% eye drops, used for the first time on a large scale to
reduce the prevalence of active forms of trachoma in a population.
The first year, mass treatment gave promising results with a
decrease in trachoma prevalence of more than 25% (from 31.5%
to 6.3%) [7]. This article presents results after two rounds of
treatment.
Methods
Mass treatment campaign
In accordance with the WHO recommendations [8], the
trachoma control programme in the Kolofata Health District
called for one mass treatment per year for three years. The
www.plosntds.org 1 November 2010 | Volume 4 | Issue 11 | e895treatment consisted in one instillation of azithromycin 1.5% in
both eyes in the morning and in the evening during three
consecutive days. The study received authorisation from the
Cameroon Ministry of Public Health in February 2008. The first
round of treatment began on 23 February 2008 and ended on 10
March 2008, and the second one was undertaken between the 5th
and 20th of January 2009 (Figure 1).
Each year, The ´a Laboratories donated 120,000 complete
treatments (720,000 single doses) of azithromycin 1.5% eye drops,
and sent them by air from Europe to Yaounde ´, Cameroon, and by
train and truck from Yaounde ´ to Kolofata.
The target population was all residents of the Kolofata Health
District [9]. The entire population was treated, but only children
between 1 and 10 year olds were examined for active trachoma.
During the 15 days preceding the beginning of treatment, the local
community health workers, helped by a literate second-level
community health worker, conducted an exhaustive door-to-door
census of all residents of the Kolofata Health District. Each of the
250 local community health workers was assigned a village or
neighbourhood of 400 to 500 residents.
The local community health workers then administered
treatment by visiting each household morning and evening for
three consecutive days. Ophthalmic nurses were supervising each
day the mass treatment in the different villages. A briefing was
organized in Kolofata hospital each evening where the supervisors
reported day after day their assessment of the mass treatment.
The studies
As described by Huguet [7], among children aged between 1
and 9 year olds (up to their 10th birthday), three descriptive cross-
sectional studies, to assess the effectiveness of treatment on the
prevalence of active forms of trachoma in the population
(trachomatous inflammation—follicular (TF) and/or trachoma-
tous inflammation—intense (TI) [10,11]), were conducted in the
Kolofata Health District. The first was conducted prior to
treatment in February 2008, the second prior the second
treatment in January 2009, and the third in January 2010, one
year after the second treatment (Figure 1). The standard WHO
protocol for trachoma prevalence surveys was used [12].
The population studied was chosen at random and was based
on the exhaustive list of villages and demographic statistics
gathered in 2006 for the national census [9] and revaluate
annually by a census at Kolofata sanitary district level only
(118,617 inhabitants in 2009).
Assuming a prevalence of less than 5% at the end of the study
(one year after the third treatment), it was necessary to include
2,400 children between 1 and 10 years in the study to obtain a
precision of approximately 1.5% with a two-sided 95% CI and a
cluster effect of 4 [13]. The 2,400 children were divided into 40
clusters, with 60 children per cluster chosen randomly.
All target-population residents (defined as children over 1 year
and less than 10 years old [up to their 10th birthday] who had
lived in the village for at least six months prior to the study date) in
randomly selected households were registered and included in the
population to be examined. When a family had left the community
Figure 1. Flow chart of the study.
doi:10.1371/journal.pntd.0000895.g001
Author Summary
Trachoma is the leading cause of infectious blindness
worldwide, accounting for 1.3 million cases of blindness.
Although it has disappeared in many regions of the world,
trachoma is still endemic in Africa, Eastern Mediterranean,
Latin America, Asia, and Australia. The WHO has currently
set a target of 2020 for controlling trachoma to a low
enough level that resulting blindness will not be a major
public health concern. Topical tetracycline was for a long
time the recommended treatment for active trachoma, but
compliance to the regimen is extremely poor. Azithromy-
cin has properties that make it an ideal treatment for
Chlamydia trachomatis: high efficacy, intracellular accumu-
lation, and a long tissue half-life. There is now a new mass
treatment of trachoma by azithromycin 1.5% eye drops
which is as effective as the oral route. In the test health
district of Kolofata, Cameroon, the prevalence of trachoma
among children dramatically decreased from 31% to less
than 5% after 2 treatments. A third treatment was
performed in January 2010. An epidemiological surveil-
lance is implemented to see if this removal will be
permanent. It also avoids misuse of oral azithromycin and
the eye drops are directly treating the site of the infection.
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empty, that household was replaced by the household nearest to it.
A household that was only ‘‘temporarily’’ empty (less than 6
months) was not replaced. The research team returned up to three
times to examine any subject absent during the preceding visit. If
after the third visit the missing person was not found, that person
was declared absent and not replaced.
Any family in the selected population whose head of household
refused consent to participate in the study was not replaced [12].
This population corresponds to the enumerated population. The
examined population corresponds to the population effectively
examined.
A two-day training session helped assure standardization of
procedures for conducting the census, examining subjects, and
collecting and recording data. A post-training test was conducted
on 50 trachoma patients to determine whether the trainee had
mastered the WHO simple grading system and to confirm that
each future examiner had a concordance of more than 80% with
an expert examiner for each key sign. A pilot study was conducted
in two villages not included in the current studies.
All children included in the study were examined by a senior
nurse who everted the upper eyelid and examined the conjunctiva
with a 2.5 magnifying glass and a torch held by an assistant who
also recorded the data. The examiner changed gloves after the
examination of each patient. Before examining the next person,
the examiner verified that the assistant had filled out the study
sheet in accordance with study protocol guidelines.
Data were compiled and analysed using EPIINFO 6 software.
Estimated confidence intervals took into account the composition
of sample clusters.
Ethics Statement
All subjects provided informed consent. As people were
illiterate, informed consent was read to people and if they agreed
to participate the participant or legally acceptable representative
put their fingerprints on the informed consent and a literate
witness signed on behalf of the participant. National ethics
committee of Yaounde approved the way to collect consent and
the study before the beginning of the study.
Results
Results of the mass treatment campaign using
azithromycin 1.5% eye drops
During the first annual treatment, azithromycin 1.5% eye drops
were administered by the local community health workers to
111,340 of the 115,274 people counted in the census (coverage
96.6%) [7]. During the second round of treatment 105,802 people
(45,288 adults and 60,514 children; 50,846 males and 54,956
females) received the full 6-dose treatment of azithromycin eye
drops. In addition, 41,376 doses were administered to others who
did not complete the full 6-dose treatment i.e. to people who were
absent during at least one of the treatment administration visit.
The number of children examined during the study relative to
the number counted in the random selected population is
presented in Table 1.
During the study, age and sex distributions were similar in the
sample populations before and after treatments (p.0.05) (Table 2).
Prevalence of trachoma before and after treatment
among children aged between 1 and 10 years
In February 2008, before all treatment, the prevalence of active
forms was estimated to be 31.5% (95%CI 26.4–37.5). One year
after the first mass treatment (January 2009), this prevalence
dropped significantly to 6.3% (95%CI 4.5–8.6) (p,0.0001). One
year after two rounds of topical treatment (January 2010),
prevalence dropped to 3.1% (95%CI 2.0–4.9) (p,0.0001)
(Table 3), a decrease of 90%.
The prevalence of TF in the study sample was estimated to be
24% (95%CI 20.7–27.5) before treatment, it decreased signifi-
cantly to 5.8% (95%CI 4.1–8) one year after first annual treatment
(p,0.0001) and again significantly (p=0.0001) to 3.1% one year
after the second round of treatment (Table 3), either a decrease of
87%. The prevalence of TI was estimated to be 7.5% (95%CI 5.7–
10) before treatment and disappeared after two annual treatments
and (0.5% after 1
st treatment (p,0.0001) and 0% after second one
(p=0.0005) (Table 3) (Figure 2).
Safety of azithromycin 1.5% mass treatment
Questionnaires concerning side effects of treatment were
administered by community health workers during daily visits.
According to WHO recommendations, if TF is 10% or more in
children 1–9 years old, a mass treatment with antibiotic should be
conducted throughout the district. Furthermore, as efficacy of the
treatment was already assessed in a Phase III study, it was ethical
that people of the communities were all treated, so there is no
control group to assess the reliability of side effects. The few
complaints recorded were local and brief (blurred vision lasting
several minutes following instillation of eye drops or transient
burning sensation in the eyes). There were no reported serious
ocular or systemic side effects.
Discussion
A statistically significant (p,0.0001) increase in trachoma
prevalence was observed between the first prevalence study
conducted in 2006 (26%) and the study conducted prior to the
first treatment in 2008 (31.5%). It suggests that there was no
secular decline trachoma in this area. However, according to the
WHO recommendation, as it was unethical to not treat some
people of this area, the mass treatment protocol do not planned to
have a control group. Thus the prevalence reduction (from 31.5 to
3.1%) of active trachoma among children of this study is likely to
be a result of the two mass treatments with azithromycin 1.5% eye
drops and prevention campaigns.
Table 1. Survey participation: children .1 year and ,10 years.
1st prevalence survey 2nd prevalence survey 3rd prevalence survey
Examined children 2517 2404 2582
Random selected children 2570 2411 2585
% participation 97.9% 99.7% 99.9%
doi:10.1371/journal.pntd.0000895.t001
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that ‘‘trachoma as a blinding disease is being controlled’’ (TF,5%
and TI,0.2%) [4]. The fact that no more TI grade (severity factor
of the disease) was observed is particularly encouraging, since TI
patients are those most likely to suffer blindness as the disease
evolves [14,15,2,12,16,17,18,19,20].
Apart from minor complaints, treatment was accepted and well
tolerated by both children and adults.
The importance of endemic trachoma in the district of Kolofata
justified the mass treatment of the entire population with
azithromycin 1.5% eye drops as part of the SAFE strategy and
in accordance with WHO recommendations [8]. The apparent
coverage decreased between 2008 and 2009 (97% to 89%) is an
artefact produced by a change in reporting: in 2009, unlike 2008,
only people who had completed all 6 doses were counted.
The most common drug currently used in trachoma mass
treatment campaigns is azithromycin 20 mg/kg taken orally. In
Niger from 2002 to 2005, SAFE strategy was implemented and
three mass treatments using oral azithromycin were performed in
2 districts with 72 villages. Surveys were conducted 3 years apart
(before and after program) The prevalence of TF among children
decreased from 62.3% and 49.5% to 7.6% and 6.7% in three
years [21], a reduction of 89% in one village and 85% in the other.
At the same period, in Mali, mass treatment using oral
azithromycin was conducted in 7 districts. The prevalence of TI
among children decreased from 33% to 2.5% in 3 years [22], a
reduction of 92.4%. In a study in Nepal where nearly 40% of
children had active trachoma, three rounds of treatment directed
at children age 1 to 10 years reduced clinically active trachoma to
approximately 13% one year after the first treatment and to 4%
one year after the second one. Furthermore, this three annual
treatments were successful in reducing infection and disease in
these children up to 6 months after the third last treatment (4% of
children with active trachoma) [23]. However, is 6 months long
enough to determine of the reduction of the disease in a
population. To assess this, one study conducted in trachoma-
hyperendemic communities in Tanzania determined, after two
rounds of mass treatment with oral azithromycin spaced 18
months apart, the rate of trachoma and infection at 5 years, either
3.5 years last treatment. Results showed that 3.5 years after two
rounds of mass treatment, trachoma was not eliminated but
antibiotherapy appeared to be associate with lower disease
prevalence: from 39.2–80.6% (according age groups) at baseline
to 7.7–49.1% 5 years after baseline [24].
Considering oral azithromycin studies published, mass treat-
ment with azithromycin 1.5% eye drops, with a reduction about
90% of active trachoma, is at least as effective as treatment with
oral azithromycin. Moreover, a phase III clinical trial showed that
topical azithromycin 1.5% twice a day for 3 days has a similar
efficacy as a single oral 20 mg/kg dose of azithromycin for the
treatment of active trachoma in children [25]. The prevalence
study planned for 2011, one year after the third annual mass
treatment with azithromycin eye drops, should be conclusive.
Finally, trachoma persists where people live in poverty without
water, sanitation, [26,1,27] and proper waste disposal [26,27].
Transmission of trachoma occurs where these conditions exist and
should be expected to return after antibiotic treatment if the
conditions are not changed. Improvements like construction of
household pit latrines and hand-dug wells will bring about
sustainable elimination of trachoma. However, the Ultimate
Intervention Goal for Environmental improvements (UIG-E)
defined by the WHO [4] is difficult to set up. Indeed, in 2008
Table 2. Comparison of the distribution of children included in the survey in 2008, 2009 and 2010 by age and sex.
1st prevalence survey 2nd prevalence survey 3rd prevalence survey
Number % Number % Number %
1–4 years 1391 55.3 1332 55.4 1386 53.7
5–9 years 1126 44.7 1072 44.6 1196 46.3
Male 1280 50.9 1236 51.4 1316 51
Female 1237 49.1 1169 48.6 1266 49
Total 2517 100 2404 100 2582 100
doi:10.1371/journal.pntd.0000895.t002
Table 3. Prevalence of active trachoma (TF, TF/TI and TF + TF/TI) before and after treatment among examined children aged
between 1 and 10 years.
TF TF/TI TF + TF/TI
n% n% n%
1st prevalence survey
N=2517
603 24%
(95%CI: 20.7–27.5)
190 7.5%
(95%CI: 5.7–10.0)
793 31.5%
(95%CI: 26.4–37.5)
2nd prevalence survey
N=2404
140 5.8%
(95%CI: 4.1–8.0)
14 0.5%
(95%CI: 0.13–1.6)
154 6.4%
(95%CI: 4.5–8.6)
3rd prevalence survey
N=2582
81 3.1%
(95%CI: 2.0–4.9)
00 %
(95%CI: 0.0–0.8)
81 3.1%
(95%CI: 2.0–4.9)
doi:10.1371/journal.pntd.0000895.t003
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Cameroon government, and two wells were built by OSF. Thus,
we are far from UIG-E, i.e. easy access to safe water for 80% of
the population [1].
Following encouraging results from the first two mass treatment
campaigns with azithromycin 1.5% eye drops, one additional mass
treatment campaign was planned. The third campaign took place
in January 2010. A fourth study to track the evolution of active
trachoma prevalence among children is planned for January 2011.
If the success of these first trachoma mass treatments with eye
drops is confirmed, eye drops treatments would be a supplemen-
tary tool to fight trachoma in particular in young children and
pregnant women.
Supporting Information
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Found at: doi:10.1371/journal.pntd.0000895.s001 (0.10 MB
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